An independent publication in Nature: Scientific Reports cites using fresh leukopaks sourced from HemaCare in their T cell cryopreservation study. The authors, who work at the Cell and Gene Therapy Catapult in London, are studying the impact of cooling and thawing rates on cryopreserved human peripheral blood-derived T cells. In order for the emerging cell and gene therapy industry to effectively ship and store cell-based therapies to global markets, it will be necessary to cryopreserve cell therapy starting materials, as well as the final therapeutic products. To retain peak cellular function, and therefore therapeutic efficacy upon patient administration, it is necessary to understand how to optimize the cryopreservation process.
Global biotechnology company Immunospot cites using B cells isolated from HemaCare-sourced peripheral blood mononuclear cells (PBMC)  for their studies on post-cryopreservation functionality.
Expectations are high that emerging field of cell therapy will be able to deliver breakthrough treatments or cures for many diseases, including cancer. One of the most powerful facets of this new medical field is the concept of immunotherapy--using the body’s own immune cells to specifically target disease. Immune cell function is at the heart of this concept, so keeping immune cells fully operational is crucially important. In this recent study published in the journal Cells, biopharmaceutical scientists aim to investigate B cell functionality following cryopreservation.
Cryopreservation of therapeutic cells allows the long-term storage of functional cells and prevents degradative processes. Fresh cells are also used for cellular therapy approaches; however, there are many circumstances that make the availability of cryopreserved cells a must for repeated and on-hand use of cells. Cell cryopreservation provides a reliable stock of cells, which reduces the variability of cell therapy product. This translates to a more standardized product that can be used on a larger scale and without constraints on optimal availability for clinical use.
Cryoport, the leading provider of advanced cryogenic solutions for the life sciences industry, announced on July 30th that it will offer cryogenic logistics solutions to HemaCare. Under this agreement, Cryoport will deliver cold chain logistics for a wide range of cell and tissue samples that can be applied to advanced biomedical research, cell therapy-based clinical trials, and product commercialization.
Cell therapy applications are quickly moving into the clinic. Cell quality is critical in providing an end product with optimal therapeutic efficacy. In the previous blogs for this series, we summarized the role of starting material in cell therapy presented by Dr. Burger and then Dr. Minger presented how cells are obtained and grown on an industrial scale. The next presenter at the HemaCare hosted panel at the International Society for Cell Therapy was Dr. Aby Mathew, Ph.D., a Scientific Advisory Board member at HemaCare and Senior VP & CTO, BioLife Solutions, Inc. presented on best practices in stability and biopreservation of cells.